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Abstract
miRNAs are small molecules involved in gene regulation. Each tissue shows a characteristic miRNAs epression profile that
could be altered during neoplastic transformation. Glioblastoma is the most aggressive brain tumour of the adult with a
high rate of mortality. Recognizing a specific pattern of miRNAs for GBM could provide further boost for target therapy. The
availability of fresh tissue for brain specimens is often limited and for this reason the possibility of starting from formalin
fixed and paraffin embedded tissue (FFPE) could very helpful even in miRNAs expression analysis. We analysed a panel of 19
miRNAs in 30 paired samples starting both from FFPE and Fresh/Frozen material. Our data revealed that there is a good
correlation in results obtained from FFPE in comparison with those obtained analysing miRNAs extracted from Fresh/Frozen
specimen. In the few cases with a not good correlation value we noticed that the discrepancy could be due to dissection
performed in FFPE samples. To the best of our knowledge this is the first paper demonstrating that the results obtained in
miRNAs analysis using Real-Time PCR starting from FFPE specimens of glioblastoma are comparable with those obtained in
Fresh/Frozen samples.
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Introduction
MicroRNAs (or miRNAs) are small (,20–22 nt) non coding
RNAs that modulate gene expression at a post-transcriptional
level. They act by binding the target mRNAs repressing
translation or regulating their degradation. Each miRNA, playing
its role through perfect and nearly perfect complementarity with
its target mRNAs, could regulate the expression of about a
hundred of genes, influencing a large spectrum of physiological
processes as different steps of cellular development, proliferation or
apoptosis regulation [1].
Many of these pathways are altered in human neoplasia; in fact
it has been demonstrated that miRNAs can act both as oncogenes
or oncosuppressors, according to their target mRNAs [2]. In fact,
in several neoplasia it has been observed that physiological
miRNAs profile resulted modified [3–7].
Glioblastoma (GBM) is a highly malignant astrocytic glioma. It
is the most frequent primary brain tumour and the most malignant
neoplasm with astrocytic differentiation and correspond to WHO
grade IV [8]. Histologically it is composed of poorly differentiated
astrocytic tumour cells, with marked nuclear atypia, high mitotic
activity, prominent microvascular proliferation and necrosis.
Neverthless the progress in neurosurgery, chemio- and radiother-
apy, molecular target identification for focused therapy (MGMT),
the clinical history of the disease is usually short (less than one year
in more than 50% of cases) [8,9].
There are several evidences that different miRNAs could be up-
or down-regulated in GBM. MiR-9/9* [10–12], miR-10a [13],
miR10b [12,14–16], miR17 [11], miR20a [11], miR-21
[11,12,14,16,17], miR26 [18], miR27a [18], miR182 [18,19],
miR-221 [12,20–22], miR-222 [22] and miR-519d [16] were
observed to be up-regulated in GBM (Table 1); on the contrary
miR-7 [14,23–25], miR-31 [14], miR34a [26,27], miR-101
[14,28], miR-137 [14,16], miR-330 [14] were recognized as
down-regulated (Table 1). The increasing evidence that miRNAs
are involved in GBM development and progression could lead to
recognise a specific miRNAs profile for this neoplasia.
It has been demonstrated that, differently from mRNA, integrity
of miRNAs is not influenced by fixation in formalin [29], probably
due to their short length and to the complex Argonaute protein-
miRNA [30]. The comparison of miRNAs expression starting
from Fresh/Frozen or FFPE (formalin fixed and paraffin
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several tissues as prostate [32,33], breast [34–36], kidney
[29,37,38], lymphatic tissue [39,40], tonsils [37], melanocytic nevi
[41], colon carcinoma [38] and in one case of oligodendroglioma
[42]. All these papers have demonstrated that there was a good
correlation in miRNAs expression analysis starting both Fresh/
Frozen and FFPE tissue. None of them, except for Nonn et al.
[32], performed dissection in Fresh/Frozen or FFPE material.
Most of miRNAs expression studies in GBM were performed on
Fresh/Frozen tissue or cell lines. In central nervous system
neoplasia, starting from FFPE tissue could be very useful because
of archival material is readily available and follow-up is often
known.
Aim of this study was to investigate the expression of 19
miRNAs in GBM starting from both Fresh/Frozen and FFPE-
dissected tissues. In these last samples, the dissection allowed to
enrich (.90%) the analysed material of neoplastic cells, limiting
the eventual contamination due to ‘‘normal near the tumour’’
fraction (e.g. lymphocytes, stroma, not neoplastic glial and
neuronal cells). In this way we would to investigate the feasibility
of miRNAs expression analysis starting from FFPE tissues in
GBM, looking for eventually differences between not dissected
Fresh/Frozen samples and FFPE-dissected tissues.
Materials and Methods
Ethic Statement
The study was approved by Ethic Committee of Azienda
Sanitaria Locale di Bologna (number of study 08075, protocol
number 139/CE of 5
th February 2009, Bologna, Italy). All patients
signed a written consent for molecular analysis and for anonymous
data publication for scientific studies and all information regarding
the human material used in this study was managed using
anonymous numerical codes.
Selection of Cases
Thirty cases of GBM were selected for miRNAs expression
analysis from cases collected at Bellaria (institute of Anatomia
Patologica, Bologna, Italy) and Bufalini (institute of Anatomia
Patologica, Cesena, Italy) Hospitals, within PERNO (Progetto
Emiliano-Romagnolo di Neuro-Oncologia) project. All specimens
were primary GBM, and patients had not undergone neoadjuvant
therapy before surgery. Patients were 14 males and 16 females,
aged from 42 to 75 years (mean 63.3 ys).
The specimens were collected no longer than 45 minutes after
removal and immediately a snap-frozen section was performed
and the material evaluated by a pathologist in order to verify if the
tissue was represented by a ‘‘high-grade glioma’’.
A sample of tissue was then incubated in RNA later solution
(Applied Biosystem, Austin, TX, U.S.A.) for 1 hour at room
temperature and stored at 280uC after quick-frozen in liquid
nitrogen. The remaining specular tissue was formalin fixed and
paraffin embedded for routine histological diagnosis. All 30
samples were diagnosed as GBM according the 2007 WHO
criteria [8].
Cell lines of prostate carcinoma (LNCaP, CRL-1740), breast
adenocarcinoma (MCF7, HTB-22) and glioblastoma (U-87 MG,
HTB14), provided by American Type Culture Collection (ATCC,
Rockville, MD, USA), were used for evaluating efficiency of
primers per each miRNA analysed.
miRNAs extraction
The ‘‘Fresh/Frozen’’ specimens and cell lines were processed
for miRNAs extraction protocol using mirVana miRNA isolation
Table 1. Name, chromosomal localization and expression
level in GBM according to previously described data of
miRNAs analysed in this study.
miRNA Localization Up/Downregulated in GBM Reference
9/9* 1q22 UP [10–12]
10a 17q21.32 UP [13]
10b 2q31.1 UP [12,14–16]
17 13q31.3 UP [11]
20a 13q31.3 UP [11]
21 17q21.31 UP [11,12,14,16,17]
26 3p22.2 UP [18]
27a 19p13.13 UP [18]
182 7q32.2 UP [18,19]
221 Xp11.3 UP [12,20–22]
222 Xp11.3 UP [22]
519d 19q13.42 UP [16]
7 9q21.3 DOWN [14,23–25]
31 9p21.3 DOWN [14]
34a 1p36.22 DOWN [26,27]
101 1p31.3 DOWN [14,28]
137 1p21.3 DOWN [14,16]
330 19q13.32 DOWN [14]
doi:10.1371/journal.pone.0035596.t001
Table 2. Name, localization and forward primer sequence of
analysed miRNAs.
miRNA Fw Primer Sequence
hsa-miR-7 TGGAAGACTAGTGATTTTGTT
hsa-miR-9 TCTTTGGTTATCTAGCTGTATG
hsa-miR-9* ATAAAGCTAGATAACCGAAAG
hsa-miR-10a ACCCTGTAGATCCGAATTTG
hsa-miR-10b ACCCTGTAGAACCGAATTTG
hsa-miR-17 CAAAGTGCTTACAGTGCAG
hsa-miR-20a TAAAGTGCTTATAGTGCAG
hsa-miR-21 TAGCTTATCAGACTGATGTTG
hsa-miR-26a CAAGTAATCCAGGATAGGC
hsa-miR-27a TTCACAGTGGCTAAGTTCC
hsa-miR-31 AGGCAAGATGCTGGCATA
hsa-miR-34a TGGCAGTGTCTTAGCTG
hsa-miR-101 TACAGTACTGTGATAACTGAA
hsa-miR-137 TTATTGCTTAAGAATACGCGT
hsa-miR-182 TTTGGCAATGGTAGAACTCAC
hsa-miR-221 GCTACATTGTCTGCTGGGTT
hsa-miR-222 GCTACATCTGGCTACTGG
hsa-miR-330 TCTCTGGGCCTGTGTCTTA
hsa-miR-519d AAGTGCCTCCCTTTAGAGT
LNA bases are underlined. Fw: forward. Hsa: Homo sapiens (human).
doi:10.1371/journal.pone.0035596.t002
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fraction was exctracted and enriched starting from 50 to 80 mg of
tissue or 3 millions of cells according to manufacturer’s protocol.
The haematoxylin and eosin (H&E) sections from FFPE
specimens were reviewed by a pathologist (GM) to select the
more informative block. Four 20 mm-thick sections were cut
followed by one H&E control slide. The tumour area selected for
the analysis was marked on the control slide to ensure, whenever
possible, greater than 90% content of neoplastic cells (avoiding
necrosis and lymphocytes). The four 20 mm-thick sections were
manually dissected under microscopic guidance according to area
selected on H&E and incubated in xylene for 3 minutes at 50uC
and, after two rinses with ethanol, miRNAs were extracted using
RecoverAll Total Nucleic Acid Isolation kit (Ambion, Austin, TX,
U.S.A.), according to manufacturer’s instructions.
Quality and quantity of smallRNAs extracted from both Fresh/
Frozen and FFPE-dissected tissue were evaluated using the Agilent
2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany)
and the Qubit fluorometer (Invitrogen, Carlsbad, CA, U.S.A.).
cDNA was obtained after a polyadenylation step and retro-
transcription were performed using SuperScript III RT enzyme
and a Universal RT Primer according to NCode miRNA first-
strand cDNA synthesis and qRT-PCR Kit protocol (Invitrogen,
Carlsbad, CA, U.S.A.).
miRNAs analysis
Nineteen miRNAs (Table 1) were selected for analysis,
according to their role in cancer and data previously published
in literature at beginning of the study [10–12,14,16–
18,20,21,24,25,27]. miR103, RNU49 and U54 were used as
endogenous controls.
Each forward primers used correspond to mature miRNA
sequence according to miRBase database (http://microrna.
sanger.ac.uk) (Table 2). Primers were modified with LNA (Locked
Figure 1. Scatter plot showing Spearman correlation between Fresh/Frozen and FFPE-dissected groups.
doi:10.1371/journal.pone.0035596.g001
Figure 2. Median fold-change calculated per each miRNA between 30 paired Fresh/Frozen and FFPE samples. The y-axis represents the
fold-change value.
doi:10.1371/journal.pone.0035596.g002
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inating between miRNAs with a single base different nucleotide
sequences (e.g. miR-10a and miR-10b, Table 2). Universal reverse
primer was provided by NCode miRNA first-strand cDNA
synthesis and qRT-PCR Kit (Invitrogen, Carlsbad, CA, U.S.A.).
Efficiency of each primer was tested by Real-Time PCR using
serial dilutions (1:1, 1:25, 1:50, 1:100) of a pool of RNA extracted
by following cell lines: U-87 MG, MCF7 and LNCaP. A run of
Real-Time PCR using as template a pool of female DNA
(Promega, Madison, WI, U.S.A.) was performed to confirm that
miRNAs primers were not able to amplify DNA.
miRNAs expression was evaluated using a AB7000 machine
(Applied Biosystem, Foster City, CA, USA) and FastStart Taq
Reagents Kit (Roche, Mannheim, Germany), with the following
program: 2 minutes at 50uC, 4 minutes at 95uC and 37 cycles with
annealing at 60uC for 30 seconds. GelStar stain (Lonza Biosci-
ence, Rockland, ME, USA) was used as Real-Time detector. No
template control for each miRNA was included in the reaction
plate. All the reactions were performed in duplicate and amplicons
run on a 3% agarose gel.
Statistical analysis
Expression values and fold-change were obtained by relative
quantification and 2
2DDCt method [43], using DataAssist 2.0 Tool
(Applied Biosystem, Foster City, CA, USA). Statistical analysis of
miRNAs expression was performed using GraphPad Prism 5.0
tool. Paired samples comparison and correlation analysis between
miRNAs expression in Fresh/Frozen and FFPE-dissected samples
were performed using Wilcoxon paired test and Spearman
Figure 3. Comparison between miRNAs expression profile in Fresh/Frozen and in FFPE specimens. a) Example of one specimen with a
good correlationof miRNAs expression profile obtainedin Fresh/Frozen (pointed line) and in FFPE specimen (squared line); b) Example of one specimen
with a correlation less than r,0.65 of miRNAs expression profile obtained in Fresh/Frozen (pointed line) and in FFPE specimen (squared line).
doi:10.1371/journal.pone.0035596.g003
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the statistical analysis.
Results
Distribution for Fresh/Frozen (FF) and FFPE samples was
found not normal, as demonstrated by the Shapiro Test
(p,0.001). For this reason, we only used non-parametric statistical
tests.
A good Spearman correlation value (r=0.7916, p,0.0001)
between the expression level of each miRNAs comparing results
obtained in fresh-frozen and in FFPE-dissected samples was
observed (Figure 1) whereas Wilcoxon paired test showed not
significant differences between the two groups (p=0.1845).
To test if the miRNAs profile obtained in Fresh/Frozen and
FFPE-dissected (FD) samples were comparable, we calculated the
median fold-change for each 30 FF samples versus 30 FD
specimens. Although miR-137, miR-20a and miR-21 were slightly
downregulated (FD/FF ratio ,22.0), the vast majority of
miRNAs were not statistically significantly different (Figure 2)
Comparison of individual miRNAs expression between Fresh/
Frozen and FFPE-dissected sample, in single paired specimen,
showed a good Spearman correlation value (r.0.65) in 25 out of
30 samples (Figure 3a) while the remaining five cases showed a
correlation ratio ,0.65 (ranged from 0.5123 to 0.6386, Figure 3b).
To investigate if discrepancy observed in the 5 cases with r,0.65
could be caused by enrichment in neoplastic cells due to dissection,
we analysed the miRNAs profiles of these 5 samples starting from
undissected FFPE material. We performed the analysis only in the 4
cases in which the H&E revealed the presence of not-neoplastic
tissue adjacent the area dissected for miRNAs analysis (Table 3). In
3 out of 4 cases analysed the Spearman correlation value increased
up the cut off of 0.65 (Table 3).
Discussion
The use of formalin-fixed paraffin embedded samples for
nucleic acid analysis in molecular study gives more disposal of
specimen for research. For this reason, miRNAs analysis starting
from FFPE samples could be of great usefulness for miRNAs
expression study. Due to their short length (19–25 nt), the mature
miRNAs seem not to be influenced by nucleic acid degradation
caused by formalin fixation [29], as happened on the contrary for
long RNA or DNA. Several papers reported the feasibility of
miRNAs expression from FFPE specimens in different tissues as
kidney, prostate and breast [32,33,35–38].
GBM is the most aggressive adult brain tumour and,
nevertheless the progresses in molecular therapy, its prognosis
remains very poor [8]. Identifying a miRNAs profile for GBM
could be very useful for better clarify prognosis and researching
new targeted drugs. For this reason, and for ‘‘opening’’ the
anatomic pathology archives even to analysis of miRNAs
expression in GBM, it is crucial determining if FFPE specimens
are suitable for this type of analysis.
Our study demonstrated, in a cohort of 30 paired GBM, that
miRNAs analysis using real-time technique could be performed
starting from FFPE samples as well as from Fresh/Frozen
specimens. The data demonstrated that there is a good correlation
(r=0.7916) between the profiles obtained starting from FFPE-
dissected samples and from fresh samples.
The real cellular composition of Fresh/Frozen sample is not well
known,infact, even if a 4 mm-thick snap-frozensection wasused for
evaluating fresh sample, the miRNAs extraction was performed
starting from 50–80 mg of not morphologically checked tissue
(containing, for example, lymphocytes or non-neoplastic cells). This
situationcould lead to discrepant resultsinmiRNAs analysisthat we
observed in 5 out of 30 cases here analysed. In FFPE-dissected
samples, the selection of area used for performing the analysis lead
to enrich the sample in neoplastic cells, avoiding ‘‘contamination’’
due to non-tumoural components. In 3 out of 4 cases, with a not
good (r,0.65) Spearman correlation value, the analysis of miRNAs
expression performed without dissection resulted in a better
correlation with corresponding Fresh/Frozen samples. In only
one case the correlation coefficientvalue remained below 0.65, even
when obtained without dissecting the sample. To our knowledge,
this sample did not show peculiar histological features (i.e.
predominant lymphocytic infiltrate or necrotic zone).
To the best of our knowledge, this is the first study comparing
the miRNAs expression analysis in GBM in FFPE-dissected
samples and Fresh/Frozen specimens.
Our data demonstrated that in a cohort of 30 GBM, as
happened in other tissues, data of miRNAs expression analysis are
comparable starting from FFPE sample as well as from Fresh/
Frozen specimens. This approach have several advantages: it is
possible to check the real composition of the analysed sample, and
it could be possible to dispose of archival material for miRNAs
expression analysis (even considering the difficult to retrieve fresh
brain tissue). The fact that dissection could influence the
expression results leads to put a lot of attention in comparing
miRNAs analysis performed with or without dissection.
Table 3. Spearman correlation values between miRNA profiles obtained in Fresh/Frozen, FFPE-dissected and FFPE-not dissected
samples.
Case
R (Fresh/Frozen vs FFPE-
dissected)
R (Fresh/Frozen vs FFPE-not
dissected) Composition of not-dissected FFPE sample
Neoplastic cells (%) Not-neoplastic cells (%)
10 . 5 1 N P 9 8 2
2 0.60 0.70 50 50
3 0.50 0.38 75 25
4 0.62 0.81 70 30
5 0.63 0.89 40 60
NP: Not Performed.
doi:10.1371/journal.pone.0035596.t003
miRNA Expression in FFPE and Fresh/Frozen GBM
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35596Acknowledgments
We would like to thank Dr. Nigrisoli Evandro from Anatomic Pathology of
Bufalini Hospital for kindly supplying cases. The authors thank Dr. Warren
Emmett from Paul O’Gorman Cancer Institute, University College
London, London, for his valuable help in the proof reading of the
manuscript.
The PERNO Study group (Affiliations are indicated between
brackets)
Steering committee:
Baruzzi A. (Chair), Albani F., Calbucci F., D’Alessandro R., Michelucci
R. (IRCCS Institute of Neurological Sciences, Bologna, Italy), Brandes A.
(Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna,
Italy), Eusebi V. (Department of Hematology and Oncological Sciences
‘‘L. & A. Seragnoli,’’ Section of Anatomic Pathology at Bellaria Hospital,
Bologna, Italy), Ceruti S., Fainardi E., Tamarozzi R. (Neuroradiology
Unit, Department of Neurosciences and Rehabilitation, S. Anna Hospital,
Ferrara, Italy), Emiliani E. (Istituto Oncologico Romagnolo, Department
of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna, Italy),
Cavallo M. (Division of Neurosurgery, Department of Neurosciences and
Rehabilitation, S. Anna Hospital, Ferrara, Italy).
Executive committee:
Franceschi E., Tosoni A. (Department of Medical Oncology, Bellaria-
Maggiore Hospitals, Bologna, Italy), Cavallo M. (Division of Neurosurgery,
Department of Neurosciences and Rehabilitation, S. Anna Hospital,
Ferrara, Italy), Fiorica F. (Department of Radiation Oncology, S. Anna
Hospital, Ferrara, Italy), Valentini A. (Division of Neurosurgery, Nuovo
Ospedale Civile S. Agostino-Estense, Baggiovara, Modena, Italy), Depenni
R. (Department of Oncology, Policlinico di Modena, Italy), Mucciarini C.
(Department of Oncology, Ramazzini Hospital, Carpi, Modena, Italy),
Crisi G. (Department of Neuroradiology, Maggiore Hospital, Parma, Italy),
Sasso E. (Department of Neurological Sciences, Maggiore Hospital,
Parma, Italy), Biasini C., Cavanna L. (Department of Oncology and
Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy), Guidetti D.
(Department of Neurology, Guglielmo da Saliceto Hospital, Piacenza,
Italy), Marcello N., Pisanello A. (Department of Neurology, Istituto in
tecnologie avanzate e modelli assistenziali in oncologia, IRCCS, S. Maria
Nuova Hospital, Reggio Emilia, Italy), Cremonini A.M., Guiducci G.
(Division of Neurosurgery, M. Bufalini Hospital, Cesena, Italy).
Registry Coordination Office: de Pasqua S., Testoni S. (IRCCS Institute
of Neurological Sciences, Bologna, Italy).
Participants:
Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E.,
Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V.,
Crisci M., Dall’Occa P., Ferro S., Franceschi C., Frezza G., GrassoV.,
Leonardi M., Mostacci B., Palandri G., Pasini E., Pastore Trossello M.,
Poggi R, Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper
P., Trocino C. (Bologna), Dall’Agata M., Faedi M., Frattarelli M., Gentili
G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W.,
Patuelli A., Strumia S. (Forlı `-Cesena), Casmiro M., Gamboni.A., Rasi F.
(Faenza, RA), Cruciani G. (Lugo, RA), Cenni P., Dazzi C., Guidi AR.,
Zumaglini F. (Ravenna), Amadori A., Pasini G., Pasquinelli M., Pasquini
E., Polselli A., Ravasio A., Viti B. (Rimini), Sintini M. (Cattolica, RN),
Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti
S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E. (Modena), Artioli F.,
Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C. (Carpi, MO),
Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G. (Reggio Emilia), Api P.,
Cartei F., Fallica E., Granieri E., Latini F., Lelli G., Monetti C., Saletti A.,
Schivalocchi R., Seraceni S., Tola M.R., Urbini B. (Ferrara), Giorgi C.
Montanari E. (Fidenza, PR), Cerasti D., Crafa P., Dascola I., Florindo I.,
Giombelli E., Mazza S., Ramponi V., Servadei F., Silini EM., Torelli P.
(Parma), Immovilli P., Morelli N., Vanzo C. (Piacenza), Nobile C.
(Padova).
Full affiliations and postal addresses of PERNO participants are
available at the study website: www.perno.it.
Author Contributions
Conceived and designed the experiments: DDB MV AP. Performed the
experiments: DDB MV. Analyzed the data: DDB MV LM GM CT SC AB
AP. Contributed reagents/materials/analysis tools: AP AB. Wrote the
paper: DDB MV AP. Statistical Analysis: CT.
References
1. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
2. Dalmay T (2008) MicroRNAs and cancer. J Intern Med 263: 366–375.
3. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA
gene expression deregulation in human breast cancer. Cancer Res 65:
7065–7070.
4. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ (2003)
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol
Cancer Res 1: 882–891.
5. Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, et al. (2011) A
miRNA expression signature that separates between normal and malignant
prostate tissues. Cancer Cell Int 11: 14.
6. Sozzi G, Pastorino U, Croce CM (2011) MicroRNAs and lung cancer: from
markers to targets. Cell Cycle 10: 2045–2046.
7. Pang JC, Kwok WK, Chen Z, Ng HK (2009) Oncogenic role of microRNAs in
brain tumors. Acta Neuropathol 117: 599–611.
8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of
Tumours of the Central Nervous System; IARC, editor. Lyon.
9. Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of
life, neurocognitive function and their correlates in glioblastoma multiforme: a
review. J Neurooncol 104: 639–646.
10. NassD,RosenwaldS,MeiriE,GiladS,Tabibian-KeissarH,etal.(2009) MiR-92b
and miR-9/9* are specifically expressed in brain primary tumors and can be used
to differentiate primary from metastatic brain tumors. Brain Pathol 19: 375–383.
11. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, et al. (2009)
Identification and functional characterization of microRNAs involved in the
malignant progression of gliomas. Brain Pathol 20: 539–550.
12. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, et al. (2005) Extensive
modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys
Res Commun 334: 1351–1358.
13. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, et al. (2010) miR-
195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide
resistance in glioblastoma multiforme cells. Cancer Lett 296: 241–248.
14. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124
and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce
differentiation of brain tumor stem cells. BMC Med 6: 14.
15. Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, et al. (2010) Human
glioma growth is controlled by microRNA-10b. Cancer Res 71: 3563–3572.
16. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, et al. (2008)
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128
inhibits glioma proliferation and self-renewal. Cancer Res 68: 9125–9130.
17. Chen Y, Liu W, Chao T, Zhang Y, Yan X, et al. (2008) MicroRNA-21 down-
regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell
T98G. Cancer Lett 272: 197–205.
18. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, et al. (2009) The
PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and
facilitates gliomagenesis in vivo. Genes Dev 23: 1327–1337.
19. Roa W, Brunet B, Guo L, Amanie J, Fairchild A, et al. (2010) Identification of a
new microRNA expression profile as a potential cancer screening tool. Clin
Invest Med 33: E124.
20. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, et al. (2009) miR-
21 and 221 upregulation and miR-181b downregulation in human grade II–IV
astrocytic tumors. J Neurooncol 93: 325–332.
21. Lukiw WJ, Cui JG, Li YY, Culicchia F (2009) Up-regulation of micro-RNA-221
(miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the
survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM).
J Neurooncol 91: 27–32.
22. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, et al. (2011) miR-
221/222 overexpession in human glioblastoma increases invasiveness by
targeting the protein phosphate PTPmu. Oncogene.
23. Skalsky RL, Cullen BR (2011) Reduced expression of brain-enriched
microRNAs in glioblastomas permits targeted regulation of a cell death gene.
PLoS One 6: e24248.
24. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009)
Regulation of epidermal growth factor receptor signaling in human cancer cells
by microRNA-7. J Biol Chem 284: 5731–5741.
25. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7
inhibits the epidermal growth factor receptor and the Akt pathway and is down-
regulated in glioblastoma. Cancer Res 68: 3566–3572.
26. Li WB, Ma MW, Dong LJ, Wang F, Chen LX, et al. (2011) MicroRNA-34a
targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer
Biol Ther 12: 477–483.
27. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al. (2009) MicroRNA-34a
inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69:
7569–7576.
miRNA Expression in FFPE and Fresh/Frozen GBM
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e3559628. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, et al. (2010) miR-
101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation,
migration, and angiogenesis. Oncotarget 1: 710–720.
29. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, et al. (2007) Systematic
analysis of microRNA expression of RNA extracted from fresh frozen and
formalin-fixed paraffin-embedded samples. RNA 13: 1668–1674.
30. Weng L, Wu X, Gao H, Mu B, Li X, et al. (2010) MicroRNA profiling of clear
cell renal cell carcinoma by whole-genome small RNA deep sequencing of
paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol
222: 41–51.
31. Li J, Smyth P, Flavin R, Cahill S, Denning K, et al. (2007) Comparison of
miRNA expression patterns using total RNA extracted from matched samples of
formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC
Biotechnol 7: 36.
32. Nonn L, Vaishnav A, Gallagher L, Gann PH (2010) mRNA and micro-RNA
expression analysis in laser-capture microdissected prostate biopsies: valuable
tool for risk assessment and prevention trials. Exp Mol Pathol 88: 45–51.
33. Leite KR, Canavez JM, Reis ST, Tomiyama AH, Piantino CB, et al. (2011)
miRNA analysis of prostate cancer by quantitative real time PCR: comparison
between formalin-fixed paraffin embedded and fresh-frozen tissue. Urol Oncol
29: 533–537.
34. Wang H, Ach RA, Curry B (2007) Direct and sensitive miRNA profiling from
low-input total RNA. RNA 13: 151–159.
35. Hasemeier B, Christgen M, Kreipe H, Lehmann U (2008) Reliable microRNA
profiling in routinely processed formalin-fixed paraffin-embedded breast cancer
specimens using fluorescence labelled bead technology. BMC Biotechnol 8: 90.
36. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, et al. (2009) Robust global
micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer
tissues. Lab Invest 89: 597–606.
37. Hoefig KP, Thorns C, Roehle A, Kaehler C, Wesche KO, et al. (2008)
Unlocking pathology archives for microRNA-profiling. Anticancer Res 28:
119–123.
38. Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, et al. (2009)
Tissues from routine pathology archives are suitable for microRNA analyses by
quantitative PCR. J Clin Pathol 62: 84–88.
39. Lawrie CH (2007) MicroRNA expression in lymphoma. Expert Opin Biol Ther
7: 1363–1374.
40. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, et al. (2008) An array-
based analysis of microRNA expression comparing matched frozen and
formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 10:
513–519.
41. Glud M, Klausen M, Gniadecki R, Rossing M, Hastrup N, et al. (2009)
MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed,
paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol
129: 1219–1224.
42. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, et al. (2004)
Microarray-based, high-throughput gene expression profiling of microRNAs.
Nat Methods 1: 155–161.
43. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
miRNA Expression in FFPE and Fresh/Frozen GBM
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35596